Drug Profile
Research programme: siRNA neuropathic pain therapeutics - Alnylam Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Neuropeptide Y receptor antagonists; RNA interference; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 06 Nov 2006 Preclinical trials in Neuropathic pain in USA (unspecified route)